Eveline Hogenkamp-van Velp

PamGene BV provides biopharmaceutical products and clinical settings. It also provides PamChip biomarkers, such as tyrosine kinases, serine/threonine kinases, nuclear receptors, and reagent kits. The firm provides BioNavigator, a software tool for interpretation of PamChip measurements, as well as for performing data analysis for various PamChip experiments; and Evolve that enables data capture and analysis, as well as for the export of data into third party software formats. The company was founded by Tim Kievits in December 1999 and is headquartered in 's-Hertogenbosch, the Netherlands.

Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands.

BioX Biosciences BV (BioX) is an privately owned venture capital firm with its headquarters in s-Hertogenbosch, The Netherlands. The firm was established in 1983.

Westertoren Innovation Ventures BV (Westertoren Innovation Ventures) is a private equity and venture capital subsidiary of Biox Biosciences BV headquartered in 's-Hertogenbosch, Netherlands. The firm was founded in 2009.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

Newtricious BV develops active food ingredients and products for health maintenance. It focuses on health areas, such as, obesity, metabolic syndrome, eye health, cardiovascular health, and diabetes. The company was founded by Jos Nelissen and Marieëtte Nelissen in 2006 and is headquartered in Oirlo, the Netherlands.

Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands.

Lupus Ventures BV provides financial services. Its headquarters are located in Heerenveen, Netherlands.